IMO, no one from inside BIIB will comment on any possible value of A2-73 MS report published today. Such comments would have to be from top BIIB exec., considering possible revenue and other unknowns, such as fit. We are talking about their current cash cow. As noted, there may be possible sensed cultural mismatch (not a good fit).
Would seem that BIIB are compelled to do A2-73 trials.